Director
Regeneron
Tarrytown, New York
Michael received his Ph.D. from Sydney University and CSIRO developing immunoassays to screen for genetic variants in plants. He moved to the US for a post doc at Columbia University where he investigated integrin-mediated cell signaling and motility. He went on to study tumorigenesis and eventually develop immunoassays to detect biomarkers of radiation exposure. Michael left academia to work at Regeneron where he led a group of scientists developing and validating PK, ADA, NAb and biomarker immunoassays for nonclinical and clinical studies. He is currently a Director in the Bioanalytical Sciences Dept and is the BA and immunogenicity strategic lead for multiple therapeutic areas, interacting directly with clinical teams including physicians, clinical pharmacology and regulatory departments.
Hot Topic: Rethinking the Immunogenicity Testing Paradigm for 21st Century Modalities
Monday, October 23, 2023
9:00 AM – 10:00 AM ET
Therapeutic Drug Monitoring: Opportunities and Technical Considerations
Wednesday, October 25, 2023
3:00 PM – 3:15 PM ET